Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer

Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer

Author Leite, Daniela B. Autor UNIFESP Google Scholar
Junqueira, Michele G. Autor UNIFESP Google Scholar
Carvalho, Cristina V. de Autor UNIFESP Google Scholar
Massad-Costa, Ana M. Autor UNIFESP Google Scholar
Gongalues, Wagner J. Autor UNIFESP Google Scholar
Nicolau, Sergio M. Autor UNIFESP Google Scholar
Lopes, Luiz A. E. Autor UNIFESP Google Scholar
Baracat, Edmundo C. Autor UNIFESP Google Scholar
Silva, Ismael D. C. G. da Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract The present case-control study evaluates the role of the progesterone receptor (PR) polymorphism known as PROGINS as a risk factor for ovarian cancer development and investigates the association between these genetic variants and clinical/pathologic variables of ovarian cancer. PROGINS polymorphism was examined, by polymerase chain reaction, in a total of 80 patients with ovarian cancer and 282 control subjects. the frequencies of PROGINS polymorphism T1/T1, T1/T2, and T2/T2 were 71.3, 15.0 and 13.8% in ovarian cancer patients and 78.37, 21.63 and 0% in controls, respectively the chi(2)-test showed a higher incidence of the T2/T2 genotype (P=0.001) in the ovarian cancer group. in addition, women carrying a mutated allele (T2) showed approximately 2.2 times higher risk of ovarian cancer development as compared to women who have a variant allele (odds ratio (OR) = 2.2; 95% CI = 1.80-3.54). Regarding the clinical and pathologic findings observed within the cancer group, there was a significant correlation between PROGINS polymorphism and patients with a familial history (chi(2) = 6.776; P = 0.009; Fischer exact test, P = 0.01). in this regard, patients with familial antecedents have a 4.7 times higher likelihood to have at least one risk allele (T2) as compared with patients without familial antecedents (OR = 4.69; 95% CI = 1.38-15.87). No correlations were observed among the other variables. These data suggest that the PROGINS polymorphism T2/T2 genotype might be associated with an increased risk of ovarian cancer. (C) 2008 Elsevier Inc. All rights reserved.
Keywords ovarian cancer
Language English
Date 2008-07-01
Published in Steroids. New York: Elsevier B.V., v. 73, n. 6, p. 676-680, 2008.
ISSN 0039-128X (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 676-680
Access rights Closed access
Type Article
Web of Science ID WOS:000255817100013

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account